Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Spyre Therapeutics, Inc.
SYRE
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.4B
$85.92
▼ -3.34%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$14.51 - $102.06
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 473.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Selective α4β7 integrin targeting with SPY001 lead candidate
- Multi-pathway combination therapy approach (SPY120, SPY130, SPY230)
- Experienced biotechnology team and research infrastructure in Waltham, Massachusetts
- Focused pipeline addressing significant IBD market opportunity
Bear Case
1 risk
- Very high volatility (beta 3.1). Expect 3x market swings. Position size accordingly.
Growth
Revenue decline expected
Advancement of SPY001 through preclinical development toward IND-enabling studies
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+86.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SYRE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 5, 2026
Reported EPS of -$0.74 vs -$0.66 consensus (-12.1% surprise).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-12.1%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$0
$0
$0
$0
$0
$0
$90.5M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
10 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$90.00
▲ +4.8% vs $85.92
Latest: Wedbush · Jun 16, 2026
9 analysts covering